PuriBlood Medical, a biomedical company listed on the Emerging Stock Board, recently announced that it has officially received a certification from the Industrial Development Bureau of the Ministry of Economic Affairs, recognizing it as a "technology-based enterprise with market potential." With this approval, PuriBlood's IPO plan is now underway, and the company is expected to submit its listing application by the end of the year.
PuriBlood highlighted four main operational focuses. First, the company’s partnership with Nan Ya Plastics has led to the establishment of Taiwan's first human-use blood bag manufacturing plant in Shulin, which is now equipped with sufficient production capacity. The plant will begin production in the fourth quarter of this year. At the same time, PuriBlood's in-line blood bag set products have obtained QMS certification, and the company is advancing towards securing CE certification for the EU market and FDA approval for the U.S. market. These certifications are expected to be completed next year, driving strong export demand and contributing to the company's growth.
In early August, PuriBlood also made a significant move by investing in a joint venture with Formosa Biomedical Technology through a technology equity transfer. This partnership aims to tap into the immunotherapy and biomedical consumables market. In addition to selling medical consumables, PuriBlood aims to become Taiwan's largest CDMO (Contract Development and Manufacturing Organization) for biomedical materials. The company will supply the joint venture with essential consumables, including filters, cell culture dishes, and culture bags.
A third major operational focus is PuriBlood’s Real-time blood bag set, which performs immediate leukocyte reduction during blood donation. The company is accelerating the patent approval process and plans to complete clinical trials and obtain certification soon.
PuriBlood's Chairman and CEO, Yen-Wen Chen, noted that the global market for blood bag filters is approximately 130 million units, with an estimated market value of NT$30 billion. However, suppliers are relatively limited, and Taiwan has virtually no domestic competition, having traditionally relied on imports. PuriBlood is actively working to penetrate this market with its blood bag filter products. Its first objective is to establish a strong foundation in the medical device industry by developing patents and manufacturing capabilities, positioning these products as critical national strategic resources. The second objective is to pave the way for the future revolution of blood filtration applications with its Real-time blood bag product.
Additionally, PuriBlood has licensed its dual-ion polymer ZW-03 manufacturing technology, "P-Tex," to Formosa Plastics. The high polymer formula began contributing royalties of around NT$20 million last year, with expectations for this amount to increase annually.
With the recent approval as a technology enterprise, PuriBlood has officially initiated its IPO plan, aiming to submit its listing application by the end of this year.
Resource (mandarin): 普瑞博獲科技事業核准函IPO計畫啟動 與南亞合作人用血袋廠第4季投產
